Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

William J Watkins

Showing results (31-40 of 48) with videos related to

Pageof 5
Sort By:
The Journal of Pharmacology and Experimental Therapeutics|February 26, 2024
Development of Cilofexor, an Intestinally-Biased Farnesoid X Receptor Agonist, for the Treatment of Fatty Liver DiseaseDavid Hollenback, Eva Hambruch, Gero Fink, et al.
Bioorganic & Medicinal Chemistry Letters|July 23, 2003
Conformationally-restricted analogues of efflux pump inhibitors that potentiate the activity of levofloxacin in Pseudomonas aeruginosaThomas E Renau, Roger Léger, Lubov Filonova, et al.
Bioorganic & Medicinal Chemistry Letters|November 19, 2003
MexAB-OprM-specific efflux pump inhibitors in Pseudomonas aeruginosa. Part 1: discovery and early strategies for lead optimizationKiyoshi Nakayama, Yohei Ishida, Masami Ohtsuka, et al.
Bioorganic & Medicinal Chemistry Letters|April 28, 2004
MexAB-OprM specific efflux pump inhibitors in Pseudomonas aeruginosa. Part 4: Addressing the problem of poor stability due to photoisomerization of an acrylic acid moietyKiyoshi Nakayama, Noriko Kuru, Masami Ohtsuka, et al.
Bioorganic & Medicinal Chemistry Letters|December 31, 2003
MexAB-OprM specific efflux pump inhibitors in Pseudomonas aeruginosa. Part 3: Optimization of potency in the pyridopyrimidine series through the application of a pharmacophore modelKiyoshi Nakayama, Haruko Kawato, Jun Watanabe, et al.
Bioorganic & Medicinal Chemistry Letters|November 24, 2016
Selectivity switch between FAK and Pyk2: Macrocyclization of FAK inhibitors improves Pyk2 potencyJulie Farand, Nicholas Mai, Jayaraman Chandrasekhar, et al.
Bioorganic & Medicinal Chemistry Letters|September 24, 2004
Quinazolinone fungal efflux pump inhibitors. Part 2: In vitro structure-activity relationships of (N-methyl-piperazinyl)-containing derivativesWilliam J Watkins, Rémy C Lemoine, Lee Chong, et al.
Bioorganic & Medicinal Chemistry Letters|March 14, 2007
Quinazolinone fungal efflux pump inhibitors. Part 3: (N-methyl)piperazine variants and pharmacokinetic optimizationWilliam J Watkins, Lee Chong, Aesop Cho, et al.
Journal of Medicinal Chemistry|October 2, 2009
RNase H active site inhibitors of human immunodeficiency virus type 1 reverse transcriptase: design, biochemical activity, and structural informationThorsten A Kirschberg, Mini Balakrishnan, Neil H Squires, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 7, 2009
Assessment of GS-9219 in a pet dog model of non-Hodgkin's lymphomaDavid M Vail, Douglas H Thamm, Hans Reiser, et al.
Pageof 5

Showing results (31-40 of 48) with videos related to

Sort By:
Pageof 5
The Journal of Pharmacology and Experimental Therapeutics|February 26, 2024
Development of Cilofexor, an Intestinally-Biased Farnesoid X Receptor Agonist, for the Treatment of Fatty Liver DiseaseDavid Hollenback, Eva Hambruch, Gero Fink, et al.
Bioorganic & Medicinal Chemistry Letters|July 23, 2003
Conformationally-restricted analogues of efflux pump inhibitors that potentiate the activity of levofloxacin in Pseudomonas aeruginosaThomas E Renau, Roger Léger, Lubov Filonova, et al.
Bioorganic & Medicinal Chemistry Letters|November 19, 2003
MexAB-OprM-specific efflux pump inhibitors in Pseudomonas aeruginosa. Part 1: discovery and early strategies for lead optimizationKiyoshi Nakayama, Yohei Ishida, Masami Ohtsuka, et al.
Bioorganic & Medicinal Chemistry Letters|April 28, 2004
MexAB-OprM specific efflux pump inhibitors in Pseudomonas aeruginosa. Part 4: Addressing the problem of poor stability due to photoisomerization of an acrylic acid moietyKiyoshi Nakayama, Noriko Kuru, Masami Ohtsuka, et al.
Bioorganic & Medicinal Chemistry Letters|December 31, 2003
MexAB-OprM specific efflux pump inhibitors in Pseudomonas aeruginosa. Part 3: Optimization of potency in the pyridopyrimidine series through the application of a pharmacophore modelKiyoshi Nakayama, Haruko Kawato, Jun Watanabe, et al.
Bioorganic & Medicinal Chemistry Letters|November 24, 2016
Selectivity switch between FAK and Pyk2: Macrocyclization of FAK inhibitors improves Pyk2 potencyJulie Farand, Nicholas Mai, Jayaraman Chandrasekhar, et al.
Bioorganic & Medicinal Chemistry Letters|September 24, 2004
Quinazolinone fungal efflux pump inhibitors. Part 2: In vitro structure-activity relationships of (N-methyl-piperazinyl)-containing derivativesWilliam J Watkins, Rémy C Lemoine, Lee Chong, et al.
Bioorganic & Medicinal Chemistry Letters|March 14, 2007
Quinazolinone fungal efflux pump inhibitors. Part 3: (N-methyl)piperazine variants and pharmacokinetic optimizationWilliam J Watkins, Lee Chong, Aesop Cho, et al.
Journal of Medicinal Chemistry|October 2, 2009
RNase H active site inhibitors of human immunodeficiency virus type 1 reverse transcriptase: design, biochemical activity, and structural informationThorsten A Kirschberg, Mini Balakrishnan, Neil H Squires, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 7, 2009
Assessment of GS-9219 in a pet dog model of non-Hodgkin's lymphomaDavid M Vail, Douglas H Thamm, Hans Reiser, et al.
Pageof 5